Risankizumab

Research use only, not for human use.

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM.

Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.

Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with Kds <10 pM.Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively.

Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production.Animal Model:Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days) Dosage:1 mg/kg Administration:i.p.; single dosage Result:Significantly inhibited IL23-induced ear swelling and cytokine production.Animal Model:Cynomolgus monkeys Dosage:1.0 mg/kg Administration:i.v. or s.c.Result:Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys.

——

Apoptosis

IL Receptor

IL Receptor

——

——

1612838-76-2

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years